AAAAAA

   
Results: 1-9 |
Results: 9
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study
Authors: Saylors, RL Stine, KC Sullivan, J Kepner, JL Wall, DA Bernstein, ML Harris, MB Hayashi, R Vietti, TJ
Citation: Rl. Saylors et al., Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study, J CL ONCOL, 19(15), 2001, pp. 3463-3469
Carboplatin is effective therapy for young children with progressive opticpathway tumors: A Pediatric Oncology Group phase II study
Authors: Mahoney, DH Cohen, ME Friedman, HS Kepner, JL Gemer, L Langston, JW James, HE Duffner, PK Kun, LE
Citation: Dh. Mahoney et al., Carboplatin is effective therapy for young children with progressive opticpathway tumors: A Pediatric Oncology Group phase II study, NEURO-ONCOL, 2(4), 2000, pp. 213-220
Low-stage medulloblastoma: Final analysis of trial comparing standard-dosewith reduced-dose neuraxis irradiation
Authors: Thomas, PRM Deutsch, M Kepner, JL Boyett, JM Krischer, J Aronin, P Albright, L Allen, JC Packer, RJ Linggood, R Mulhern, R Stehbens, JA Langston, J Stanley, P Duffner, P Rorke, L Cherlow, J Friedman, HS Finlay, JL Vietti, TJ Kun, LE
Citation: Prm. Thomas et al., Low-stage medulloblastoma: Final analysis of trial comparing standard-dosewith reduced-dose neuraxis irradiation, J CL ONCOL, 18(16), 2000, pp. 3004-3011
"Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group study
Authors: Brown, HG Kepner, JL Perlman, EJ Friedman, HS Strother, DR Duffner, PK Kun, LE Goldthwaite, PT Burger, PC
Citation: Hg. Brown et al., "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group study, J NE EXP NE, 59(10), 2000, pp. 857-865
Cyclophosphamide for the treatment of progressive low-grade astrocytoma: Apediatric oncology group phase II study
Authors: Kadota, RP Kun, LE Langston, JW Burger, PC Cohen, ME Mahoney, DH Walter, AW Rodman, JH Parent, A Buckley, E Kepner, JL Friedman, HS
Citation: Rp. Kadota et al., Cyclophosphamide for the treatment of progressive low-grade astrocytoma: Apediatric oncology group phase II study, J PED H ONC, 21(3), 1999, pp. 198-202
Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma
Authors: Reardon, DA Entrekin, RE Sublett, J Ragsdale, S Li, H Boyett, L Kepner, JL Look, AT
Citation: Da. Reardon et al., Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma, GENE CHROM, 24(3), 1999, pp. 230-237
Group sequential designs for Phase II trials with historical controls
Authors: Chang, MN Shuster, JJ Kepner, JL
Citation: Mn. Chang et al., Group sequential designs for Phase II trials with historical controls, CONTR CL TR, 20(4), 1999, pp. 353-364
Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study
Authors: Kadota, RP Stewart, CF Horn, M Kuttesch, JF Burger, PC Kepner, JL Kun, LE Friedman, HS Heideman, RL
Citation: Rp. Kadota et al., Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study, J NEURO-ONC, 43(1), 1999, pp. 43-47
Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome
Authors: Tihan, T Fisher, PG Kepner, JL Godfraind, C McComb, RD Goldthwaite, PT Burger, PC
Citation: T. Tihan et al., Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome, J NE EXP NE, 58(10), 1999, pp. 1061-1068
Risultati: 1-9 |